2. UroToday Home
  3. Categories

Prostate Cancer

Neoadjuvant Fc-Enhanced Anti-CTLA-4 Targets Tregs to Augment Androgen Deprivation in High-Risk Prostate Cancer: A Randomized Phase I Trial - Beyond the Abstract

Details
Even after radical prostatectomy with curative intent, a substantial proportion of men with high-risk prostate cancer will experience disease recurrence. Currently, there is no role for neoadjuvant therapy to reduce recurrence risk. Immunotherapy is a particularly interesting approach in this setting, given the potential for anti-tumor immune responses to be durable.

Younger Age Is Associated With Early Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy.

Details

To evaluate whether an age < 55 years is independently associated with early urinary continence recovery after robot-assisted radical prostatectomy (RARP) in a large multi-institutional Japanese cohort.

Progression-free Survival Following Primary Staging with [18F]PSMA-1007-PET/ceCT Versus Na[18F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial.

Details

To compare progression-free survival (PFS) in newly diagnosed prostate cancer (PCa) staged with prostate-specific membrane antigen prostate-specific membrane antigen 1007 ([18F]PSMA-1007)-positron emission tomography/contrast-enhanced computed tomography (PET/ceCT) versus sodium fluoride (Na[18F]F)-PET/ceCT.

High folate receptor expression is associated with aggressive features in prostate cancer with low prostate-specific membrane antigen expression.

Details

This work aimed to analyse the expression of and correlation between folate transporters FOLR1, FOLR2, SLC19A1 (reduced folate carrier, RFC), and FOLH1 (PSMA mRNA) in a large cohort of prostate cancer samples, with the goal of better understanding the nature of aggressive disease with low PSMA expression.

Neuroendocrine Transformation Without PSA Elevation in High-Risk Metastatic Castration-Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report.

Details

Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration-sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate-specific antigen.

Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria.

Details

While guidelines state that patients with NCCN favorable intermediate risk (FIR) prostate cancer (PCa) may consider active surveillance (AS), there is a relative lack of longer term follow up data informing AS inclusion criteria of patients with Grade Group (GG) 2 prostate cancer in the MRI era.

Aglatimagene Besadenovec (CAN-2409) with Radiotherapy for Patients with Localised Prostate Cancer: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial - Beyond the Abstract

Details
The publication of our phase 3 trial of aglatimagene besadenovec in The Lancet Oncology represents an important milestone in the treatment of localized prostate cancer. While the primary publication describes the achievement of the study's primary and secondary endpoints, several aspects of the data deserve additional discussion because they may help inform future research and clinical practice.

Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)

Details
First digital pathology-based test to provide individual risk estimates to help inform treatment planning in mHSPC

Las Vegas, Nevada (UroToday.com) -- Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the clinical availability of the ArteraAI Prostate Test (mHSPC), the first digital pathology–based prognostic test designed to help inform treatment planning for patients with metastatic hormone‑sensitive prostate cancer (mHSPC).

Prospective Multicenter Randomized Controlled Trial of Stabilized Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results

Details
The 2026 ESTRO annual meeting featured a prostate cancer session and a presentation by Dr. Martin King discussing 3-year results from a prospective multicenter randomized controlled trial of stabilized hyaluronic acid spacer for hypofractionated prostate radiation therapy. Over the last decade, there has been an increase in utilization of moderate hypofractionated radiotherapy for low risk and favorable intermediate risk prostate cancer:1

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.

Details

The objective was to develop prognostic models that included convolutional neural networks (CNN) derived from 18F-DCFPyL (PSMA) PET imaging of the primary tumor uptake patterns to prognose early metastatic progression after curative intent treatment for localized prostate cancer.

Page 1 of 3269